These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36730619)

  • 1. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.
    Bamias A; Zakopoulou R; Tzannis K; Sakellakis M; Koutsoukos K; Kyriazoglou A; Panagiotou A; Armylagos S; Rokas K; Gotzias D; Boulouta A; Bozionelou V; Stravodimos K; Varkarakis I; Mavroudis D; Dimopoulos MA
    Anticancer Drugs; 2023 Mar; 34(3):413-421. PubMed ID: 36730619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
    Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
    J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
    Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
    Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan.
    Chandler C; Burnett H; Schaible K; Senthil V; Kato M; Miura Y; Osawa T; Uemura H; Kuwabara H
    J Med Econ; 2023; 26(1):1009-1018. PubMed ID: 37505931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study.
    Işık D; Kınıkoğlu O; Akdağ G; Altıntaş YE; Türkoğlu E; Yildirim S; Sürmeli H; Başoğlu T; Odabaş H; Turan N
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064516
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
    Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
    Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.
    Karner C; Kew K; Wakefield V; Masento N; Edwards SJ
    BMJ Open; 2019 Mar; 9(3):e024691. PubMed ID: 30826762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
    Géczi L; Bodoky G; Rokszin G; Fábián I; Torday L
    Pathol Oncol Res; 2020 Oct; 26(4):2201-2207. PubMed ID: 32291570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
    Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.